BridgeBio’s Achondroplasia Data Portend Competition With BioMarin’s Voxzogo
Already planning to position infigratinib as a safer, more convenient oral therapy for dwarfism compared with the BioMarin injectable, BridgeBio now has Phase II efficacy data showing a higher growth rate.
You may also be interested in...
Finance Watch: Biotech Valuations Seesaw On Bank Failure, Pharma M&A
Public Company Edition: The closure of Silicon Valley Bank sank biotech stocks in the first full week of March, but valuations rose the next week when two big acquisitions were announced. Also, J&J’s consumer health spinout sold $7.75bn in notes ahead of its future IPO and Karuna grossed $400m in a follow-on offering.
EU Filing For Infigratinib Pulled After Commercial Deal Crumbles
BridgeBio’s partner Helsinn terminated its agreement to commercialize infigratinib, which was approved in the US last year for treating the rare bile duct cancer, cholangiocarcinoma.
BioMarin’s Voxzogo Predicted For Blockbuster Sales, But Market Must Be Built
Very early launch numbers look good in France and Germany, but US launch will be more challenging due to a fragmented patient base, the company said. Launch price is a flat $899 per vial.